(Albany, US), October 11, 2026 – DelveInsight’s ‘Hepatic Encephalopathy Market Insights, Epidemiology and Market Forecast – 2042’ report delivers an in-depth understanding of Hepatic Encephalopathy, historical and forecasted epidemiology, as well as the Hepatic Encephalopathy market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Explore the intricate details of the Hepatic Encephalopathy Market Report @ Hepatic Encephalopathy Treatment Market Size
Key Takeaways from the Hepatic Encephalopathy Market Report
In February 2025, Yaqrit announced that its recently acquired ammonia scavenger, L-ornithine phenylacetate (OPA), is progressing to Phase III for treatment of acute hepatic encephalopathy, a life-threatening complication of decompensated cirrhosis.
According to DelveInsight’s analysis, the Hepatic Encephalopathy Treatment Market Size was found to be ~USD 950 million in the 7MM in 2025 and is projected to reach ~USD 1200 million by 2042, growing at a CAGR of ~1.5% during 2026-2042.
In 2025, the United States held the largest Hepatic Encephalopathy Drugs Market Share among the 7MM, accounting for approximately 64% of the total market.
The current Hepatic Encephalopathy Therapeutics Market Size includes one approved drug, Xifaxan (Rifaximin), to reduce the risk of recurrence of OHE and for the improvement of hyperammonemia in hepatic encephalopathy, as well as several other therapies.
In 2022, Xifaxan captured a Hepatic Encephalopathy market size of ~USD 111 million (revenue from monotherapy use of rifaximin in CHE) in the 7MM.
In 2025, Rifaximin in combination with Lactulose led the US Hepatic Encephalopathy treatment market and is projected to retain its position as the dominant market leader through 2042.
The total number of prevalent cases of Hepatic Encephalopathy in the 7MM was nearly 356,500 in 2025 and is projected to increase during the forecast period.
The United States contributed the largest share of diagnosed prevalent cases of Hepatic Encephalopathy, accounting for ~60% in 2025.
The leading Hepatic Encephalopathy Companies include BAUSCH Health, Vedanta Biosciences, Yaqrit Discovery Ltd, and others.
Promising Hepatic Encephalopathy Therapies include Xifaxan (Rifaximin), Rifaximin SSD, VE303, YAQ007, and others.
Get a Free sample for the Hepatic Encephalopathy Market Forecast, Size & Share Analysis Report @ Hepatic Encephalopathy Therapeutics Market
Hepatic Encephalopathy Overview
Hepatic Encephalopathy (HE) is a diagnosis of exclusion characterized by a spectrum of neuropsychiatric disturbances resulting from the accumulation of neurotoxins in patients with liver dysfunction or portosystemic shunting. It differs in presentation and pathophysiology between chronic liver disease, acute liver failure, and acute-on-chronic liver failure, with mechanisms extending beyond hyperammonemia to include systemic inflammation, gut dysbiosis, altered neurotransmission, oxidative stress, manganese deposition, and other toxins. HE is broadly classified into covert (minimal HE and West Haven grade 1) and overt (grades 2–4) forms, representing a continuum of severity. Overt HE is defined by disorientation or asterixis, while minimal HE, affecting up to 80% of patients with cirrhosis, requires specialized testing for detection.
Hepatic Encephalopathy Diagnosis
Hepatic Encephalopathy requires initial assessment of airway and vital signs, followed by detailed history and examination to identify triggers and rule out mimics such as alcohol withdrawal. Laboratory evaluation includes arterial blood gas, blood glucose, liver function tests, coagulation profile, renal function, and electrolytes, with attention to infection markers when indicated. Although ammonia levels are often elevated, they are not diagnostic and correlate poorly with severity, though normal levels have high negative predictive value. Psychometric tests such as the Number Connection Test and Critical Flicker Frequency are sensitive for minimal HE, while EEG may show nonspecific changes and help exclude seizures. CT or MRI is used to rule out structural causes.
Hepatic Encephalopathy Epidemiology Segmentation in the 7MM
Hepatic Encephalopathy Total Diagnosed Prevalent Cases
Hepatic Encephalopathy Gender-specific Cases
Hepatic Encephalopathy Age-specific Cases
Hepatic Encephalopathy Type-specific Cases
Hepatic Encephalopathy Grade-specific Cases
Hepatic Encephalopathy Patients with Ascites
Download the report to understand which factors are driving Hepatic Encephalopathy Epidemiology trends @ Hepatic Encephalopathy Prevalence
Hepatic Encephalopathy Epidemiology Key Findings
Hepatic Encephalopathy predominantly affected males, with approximately 144,000 males diagnosed compared to 67,000 females in the US in 2025.
In the EU4 and the UK, individuals between the ages of 45-54 were the most affected by Hepatic Encephalopathy, with approximately 24,000 cases reported in 2025.
Among the EU4 and the UK, Germany had the highest number of Hepatic Encephalopathy cases with ~20,000, followed by the UK with ~16,100 and France with ~16,000, while Spain had the fewest, with ~11,000 cases in 2022.
Based on severity, there were a total of ~120,000 CHE and ~80,000 OHE cases in the United States in 2022.
In the 7MM, the total number of Hepatic Encephalopathy patients with ascites was ~225,000 in 2025, and this is expected to increase by 2042. In the US, such patients numbered approximately 100,000 in 2022.
Approved Therapies for Hepatic Encephalopathy
Xifaxan (Rifaximin): BAUSCH Health
Xifaxan (rifaximin) 550 mg tablets, developed and marketed by Salix Pharmaceuticals (a subsidiary of BAUSCH Health), are indicated to reduce the risk of recurrent overt hepatic encephalopathy in adults aged ≥18 years. Rifaximin is a non-absorbed, broad-spectrum, gastrointestinal-selective antibiotic derived from rifamycin that targets Gram-positive and Gram-negative, aerobic and anaerobic ammonia-producing bacteria, thereby lowering systemic ammonia levels implicated in hepatic encephalopathy. Unlike systemic antibiotics, rifaximin remains within the gastrointestinal tract without significant absorption and exerts its effect by binding to the β-subunit of bacterial DNA-dependent RNA polymerase, inhibiting transcription. It was first approved in the US in 2010.
Hepatic Encephalopathy Pipeline Analysis
VE303: Vedanta Biosciences
VE303 is an orally administered, wholly owned defined bacterial consortium composed of eight live commensal strains, formulated as a standardized oral pharmaceutical product manufactured from pure clonal cell banks to ensure consistent quality. The selected strains function synergistically by competing with C. difficile for growth substrates and producing secondary bile acids that suppress its proliferation, as well as short-chain fatty acids that enhance gut barrier integrity and mitigate intestinal inflammation. It is currently in Phase II development for the treatment of Hepatic Encephalopathy, with an anticipated US launch in 2028.
YAQ007: Yaqrit Discovery Ltd.
YAQ007 is an oral ammonia-scavenging agent currently in Phase II development for Hepatic Encephalopathy.
Discover more about therapies set to grab Major Hepatic Encephalopathy Market Share @ Hepatic Encephalopathy Market Drivers and Barriers
Hepatic Encephalopathy Market Outlook
Hepatic Encephalopathy is a multifactorial condition involving hyperammonemia, systemic inflammation, gut dysbiosis, neurotransmitter imbalances, and neurotoxins such as manganese. Current management centers on reducing intestinal ammonia production and absorption. Non-absorbable disaccharides such as lactulose and lactitol remain the cornerstone of therapy, used for acute episodes as well as primary and secondary prevention, with lactitol demonstrating comparable efficacy to lactulose and possibly improved tolerability in some patients. Antibiotics aimed at colonic decontamination, including neomycin, metronidazole, and vancomycin, further decrease ammonia-producing gut bacteria and may also mitigate inflammation and endotoxemia. Second-line therapies and Hepatic Encephalopathy Emerging Therapies include polyethylene glycol 3350–electrolyte solution, ammonia scavengers, branched-chain amino acids, fecal microbiota transplantation, and L-ornithine L-aspartate. Currently, only one drug is approved for Hepatic Encephalopathy treatment, Xifaxan (Rifaximin), an oral small molecule. Hepatic Encephalopathy Companies, including Vedanta Biosciences, Yaqrit Discovery Ltd, and others, are investigating candidates through approaches such as microbiome modulation (VE303) and ammonia-scavenging agents (YAQ007). Overall, the launch of Hepatic Encephalopathy therapies, improved diagnosis, and rising disease awareness are expected to drive steady growth in the 7MM Hepatic Encephalopathy market from 2022–2042.
Hepatic Encephalopathy Treatment Landscape
Management of Hepatic Encephalopathy involves supportive care, correction of precipitating factors, and ammonia-lowering therapy. Patients require adequate nutrition without protein restriction (35–40 kcal/kg/day; 1.2–1.5 g/kg/day protein), proper hydration, electrolyte correction, and a safe environment while avoiding sedatives. Triggers such as constipation, infections, electrolyte imbalance, hypovolemia, renal dysfunction, and sedative use must be promptly treated. First-line therapy is lactulose (titrated to 2–3 soft stools daily), with rifaximin added for recurrence or inadequate response; lactitol and L-ornithine-L-aspartate are alternatives. Refractory cases due to portosystemic shunts may require shunt occlusion procedures, while liver transplantation is indicated in advanced cirrhosis and can reverse cognitive impairment. Long-term prevention includes maintenance lactulose ± rifaximin and management of sarcopenia with nutrition and exercise.
Key Factors Driving the Growth of the Hepatic Encephalopathy Market
High Unmet Need for Effective and Approved Therapies: Current HE management largely depends on off-label therapies and demonstrates variable efficacy with safety concerns during long-term use. The absence of multiple approved disease-specific therapies creates significant opportunities for novel agents capable of delivering durable clearance with improved tolerability.
Expanding Clinical Development Pipeline: The HE pipeline has expanded considerably, with multiple investigational therapies progressing through clinical development. Novel monoclonal antibodies, immune modulators, kinase inhibitors, and other targeted therapies are being evaluated to address patients who remain refractory to conventional treatments. Positive clinical trial outcomes and potential regulatory approvals are anticipated to accelerate market growth.
To know more about Hepatic Encephalopathy Companies working in the treatment market, visit @ Hepatic Encephalopathy Market Access and Reimbursement
Scope of the Hepatic Encephalopathy Market Report
Coverage- 7MM
Study Period- 2022-2042
Historical Year- 2022-2025
Base Year- 2026
Forecast Period- 2026-2042
Hepatic Encephalopathy Market CAGR- ~1.5% (2026-2042)
Hepatic Encephalopathy Companies- BAUSCH Health, Vedanta Biosciences, Yaqrit Discovery Ltd, and others.
Hepatic Encephalopathy Therapies- Xifaxan (Rifaximin), Rifaximin SSD, VE303, YAQ007, and others.
Hepatic Encephalopathy Market Dynamics: Hepatic Encephalopathy market drivers and market barriers
Hepatic Encephalopathy Competitive Intelligence Analysis: Addressable Patient Population, Cost Assumptions and Pricing Analogues, SWOT Analysis, Conjoint Analysis
Hepatic Encephalopathy Unmet Needs, KOL Views, Reimbursement
Table of Contents
Key Insights
Report Introduction
Executive Summary
Key Events
Epidemiology and Market Forecast Methodology
Hepatic Encephalopathy Market Overview at a Glance
Hepatic Encephalopathy: Overview
Diagnosis
Treatment & Management
Epidemiology and Patient Population
Patient Journey
Marketed Drugs
Emerging Drugs
Hepatic Encephalopathy: Seven Major Market Analysis
Unmet Needs
SWOT Analysis
KOL Views
Market Access and Reimbursement
Appendix
DelveInsight Capabilities
Disclaimer
About DelveInsight
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Abhishek kumarEmail: Send EmailPhone: +91 9568243403Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/report-store/hepatic-encephalopathy-market
